FO
ISEE

FT Options’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

FT Options’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-32,300
Closed -$761K – 377
2016
Q4 		$761K Buy
32,300
+15,300
+90% +$454K 0.87% 30
2016
Q3 		$355K Buy
17,000
+5,000
+42% +$282K 0.28% 72
2016
Q2 		$250K Buy
+12,000
New +$596K 0.21% 87

Other funds holding ISEE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FT Options's ISEE Position: Q1 2017 in Review

FT Options sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2017, closing a stake of 26 shares.

FT Options first reported a position in ISEE in Q2 2016 and held it in 3 quarters. The position peaked at $218K in Q2 2016. 100 funds tracked by Wall St. Rank hold ISEE as of Q1 2017.

  • FT Options reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 26 IVERIC bio, Inc. Common Stock shares in Q1 2017.
  • FT Options first reported a position in IVERIC bio, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • FT Options's IVERIC bio, Inc. Common Stock position peaked at $218K in Q2 2016.
  • 100 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.